We are pleased to announce that our drug development activities were featured on NHK BS Television’s “International News,” broadcast on November 26, 2025.
The broadcast focused on the development of Taiwan’s biotechnology industry and related drug development initiatives through collaboration between Japan and Taiwan.
Through collaborative research with domestic and international universities and research institutes, we are developing drugs for a wide range of diseases, including anti-aging, longevity, and cancer. In particular, in Taiwan, we are collaborating with Taipei Medical University (TMU) to promote joint research and development of the PAI-1 inhibitor RS5614 and AI-based programmable medical devices (announced on August 30 and November 5, 2024). These efforts aim to promote clinical research and commercialization in Taiwan.
These collaborative research and development efforts are expected to contribute to the advancement of Taiwan’s biotechnology industry and strengthen its international competitiveness. The broadcast introduced the specifics of the drug development being carried out jointly by our company and Taipei Medical University.
https://www.web.nhk/tv/an/kokusaihoudou/pl/series-tep-8M689W8RVX/ep/P3RKX7KM57
Related links
“Announcement of the joint R&D collaboration agreement for artificial intelligence (AI)-based software as a medical device (SaMD) with Taipei Medical University (TMU)-Biotech Co., Ltd.” (Disclosed on August 30, 2024)
https://www.renascience.co.jp/wp-content/uploads/2024/11/24-0830Announcement-of-the-joint-RD-collaboration-agreement-for-artificial-intelligence-AI-based-software-as-a-medical-device-SaMD-.pdf
“Notice of the completion of a joint development agreement with Taipei Medical University (TMU)-Biotech Co., Ltd. (Taipei) for the PAI-1 inhibitor RS5614.” (Disclosed on November 5, 2024)
https://contents.xj-storage.jp/xcontents/AS09109/905ae85d/a278/4fe5/ac0b/cf74a3a5c4fc/140120241105510594.pdf